New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
17th March 2023
17th March 2023
17th March 2023
24th February 2023
20th February 2023
16th February 2023
US - Utah: Senate Bill 91, which was passed by the Senate last week, has been passed by the House with a minor amendment which will need to be approved by the Senate before going to the governor. The bill would change the state’s medical cannabis laws in various ways, including removing a cap on the number of licences for testing laboratories, modifying labelling requirements, and requiring heavy metal testing for vape cartridges.
15th February 2023
US - Utah: Senate Bill 137, which has been passed by the Senate and now heads to the House, would modify the state’s medical cannabis laws in several ways, including requiring terpene testing and disclosure of terpene profiles for certain products. It would also extend the expiry date of medical cannabis cards from six months to a year after issuing unless the practitioner recommends a shorter period.
7th February 2023
US - Utah: Senate Bill 91 has been passed by the Senate and now heads to the House. It would amend the state’s medical cannabis laws in various ways, including removing a cap on the number of licences for testing laboratories, modifying labeling requirements, and requiring heavy metal testing for vape cartridges.
19th January 2023
US - Utah: The House has passed House Bill 72 on medical cannabis governance, which now moves to the Senate. It would make various amendments to the state’s medical cannabis programs, such as allowing delivery of medical cannabis products directly from licensed processors under certain conditions, and shifting regulation of pharmacies to the Department of Agriculture and Food.
4th November 2022
20th July 2022
US - Utah: The Utah Department of Agriculture and Food (UDAF) has proposed new rules regarding hemp products and cannabis processing. Under the proposals, which are open to public comment until 15th August, hemp-derived cannabinoid products – which would include any THC analog such as delta-8 – could only contain up to 0.3% THC and from 1st December 2022 could contain only “a combined amount of total THC and any THC analog that does not exceed 10% of the total cannabinoid content”. The proposed rule expressly excludes some cannabinoids, such as CBD, CBG, and CBN, from being considered “THC analogs”.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.